本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Ventyx Biosciences, Inc.

1.07
+0.01000.94%
盘后1.03-0.0400-3.74%17:21 EDT
成交量:89.76万
成交额:95.01万
市值:7,610.92万
市盈率:-0.54
高:1.10
开:1.06
低:1.03
收:1.06
数据加载中...
2023/05/03

关联方拟减持公告

144 - Report of proposed sale of securities
2023/04/28

关联方拟减持公告

144 - Report of proposed sale of securities
2023/04/07

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2023/03/23

重要事件披露

8-K - Current report
2023/03/23

年度报告

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2023/03/22

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2023/03/02

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2023/02/14

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/01/30

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2023/01/26

重要事件披露

8-K - Current report
2023/01/12

重要事件披露

8-K - Current report
2023/01/05

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans
2022/12/30

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/12/20

重要事件披露

8-K - Current report
2022/12/16

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/12/15

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/12/12

重要事件披露

8-K - Current report
2022/11/30

重要事件披露

8-K - Current report
2022/11/09

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/11/04

季度报告

10-Q - Quarterly report [Sections 13 or 15(d)]